March 19 (Reuters) - Seelos Therapeutics' ( SEEL )

experimental drug for a neurological disorder called ALS, or

amyotrophic lateral sclerosis, failed to meet the main goal in a

mid-stage trial, the company said on Tuesday.

Shares of the company plunged 51% to 44 cents in trading

before the bell.

The drug, SLS-005, did not show statistical significance in

improving function and mortality during the trial.

ALS is a rare disease that can affect nerve cells in the

brain and spinal cord responsible for muscle movements, leading

to progressive paralysis and death.